Subscribe to Newsletter

Applying the 2023 ASCO-CAP guideline updates for HER2 testing in breast cancer

The 2023 ASCO-CAP guideline updates for HER2 testing in breast cancer focused on assessment and reporting practices for HER2-low (HER2 IHC 1+, IHC 2+/ISH-) expression. As HER2-low classification can impact decisions made by the clinical care team, it is important to standardize clinical practice to ensure tumors with low levels of HER2 expression are assessed and reported consistently.

Our latest application note discusses how pathology laboratories can implement the 2023 ASCO-CAP guideline update recommendations in practice, with examples from a pathologist who has already started integrating them into their institution.

>> Download app note as a PDF

>Enjoy our FREE content!

Log in or register to gain full unlimited access to all content on the The Pathologist site. It’s FREE!

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine